<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0041364" disease_type="Disease or Syndrome" abbrv="">Tumor lysis syndrome</z:e> (TLS) is a potential complication characterized by <z:hpo ids='HP_0002149'>hyperuricemia</z:hpo>, <z:hpo ids='HP_0002905'>hyperphosphatemia</z:hpo>, <z:hpo ids='HP_0002153'>hyperkalemia</z:hpo> and <z:hpo ids='HP_0002901'>hypocalcemia</z:hpo> due to massive <z:mp ids='MP_0001651'>necrosis</z:mp> of malignant cells after cytotoxic therapy </plain></SENT>
<SENT sid="1" pm="."><plain>This fatal complication occurs frequently in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e>, such as <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> and Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and in other <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with high proliferative rates and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burdens </plain></SENT>
<SENT sid="2" pm="."><plain>TLS is rarely associated with the treatment of <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Herein, we report a case of TLS following the initial administration of effective chemotherapy for an epithelioid <z:hpo ids='HP_0100243'>leiomyosarcoma</z:hpo> with focal rhabdomyosarcomatous differentiation of the uterus </plain></SENT>
</text></document>